GR1003861B - Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. - Google Patents

Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Info

Publication number
GR1003861B
GR1003861B GR20000100470A GR2000100470A GR1003861B GR 1003861 B GR1003861 B GR 1003861B GR 20000100470 A GR20000100470 A GR 20000100470A GR 2000100470 A GR2000100470 A GR 2000100470A GR 1003861 B GR1003861 B GR 1003861B
Authority
GR
Greece
Prior art keywords
present
anxiety
neurosteroids
formula
compounds
Prior art date
Application number
GR20000100470A
Other languages
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Priority to GR20000100470A priority Critical patent/GR1003861B/el
Priority to US10/250,334 priority patent/US7064116B2/en
Priority to AU2002217353A priority patent/AU2002217353A1/en
Priority to PCT/GR2001/000048 priority patent/WO2002053577A2/en
Publication of GR1003861B publication Critical patent/GR1003861B/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027Azides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

παρούσα εφεύρεση αναφέρεται σε νέα ανάλογα στεροειδών τα οποία επιδρούν στον ιοντοφόρο σύμπλεγμα υποδοχέας γ-αμινοβουτυρικού οξέος-κανάλι χλωρίου καθώς επίσης και μεθόδους για τη σύνθεση αυτών και εφαρμογή τους σαν αναισθητικά, για την αντιμετώπιση του stress, άγχους, αυπνίας, επιληψίας , PMS, PDN και για τη βελτίωση ή πρόληψη επεισοδίων άγχους, μυικής τάσης και κατάθλιψης οι οποίες είναι καταστάσεις που απαντώνται σε ασθενείς που υποφέρουν απο διαταραχές του κεντρικού νευρικού συστήματος. Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του τύπου (Ι) όπου τα R1,R2,R3,R4,R5 προσδιορίζονται στην Περιγραφή της εφεύρεσης Επίσης μέρος της εφεύρεσης αποτελούν και φαρμακοτεχνικές μορφές που περιλαμβάνουν μία ή και περισσότερες απο τις ενώσεις του τύπου (Ι). ΰ
GR20000100470A 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. GR1003861B (el)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
US10/250,334 US7064116B2 (en) 2000-12-29 2001-12-21 GABAA modulating neurosteroids
AU2002217353A AU2002217353A1 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids
PCT/GR2001/000048 WO2002053577A2 (en) 2000-12-29 2001-12-21 Gabaa modulating neurosteroids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Publications (1)

Publication Number Publication Date
GR1003861B true GR1003861B (el) 2002-04-11

Family

ID=10944475

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000100470A GR1003861B (el) 2000-12-29 2000-12-29 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.

Country Status (4)

Country Link
US (1) US7064116B2 (el)
AU (1) AU2002217353A1 (el)
GR (1) GR1003861B (el)
WO (1) WO2002053577A2 (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2009219230A1 (en) * 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CZ302050B6 (cs) * 2009-08-04 2010-09-15 Ústav organické chemie a biochemie, Akademie ved CR, v.v.i. 3alfa-Hydroxy-21ksí,22-oxido-21-homo-5alfa-pregnan-20-on, zpusob jeho výroby a jeho použití
AU2011284606A1 (en) * 2010-07-30 2013-03-14 Pharmacellion Ltd Compounds and methods for treating neoplasia
US9388210B2 (en) 2011-02-25 2016-07-12 Washington University Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
CN113956315B (zh) 2011-09-08 2024-08-09 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
IL275725B (en) 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
TR201808616T4 (tr) 2012-12-18 2018-07-23 Sage Therapeutics Inc Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
EP3932932A1 (en) * 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
HUE041369T2 (hu) 2013-04-17 2019-05-28 Sage Therapeutics Inc 19-nor C3,3-diszubsztituált C21-N-pirazolil-szteroidok és eljárás ezek alkalmazására
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CA3199003A1 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3235088A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MX2017005002A (es) 2014-10-16 2018-01-23 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos del snc.
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
RS61530B1 (sr) 2015-01-26 2021-04-29 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
MX2020011449A (es) 2015-07-06 2022-02-28 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10696712B2 (en) 2015-07-06 2020-06-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR102408399B1 (ko) 2016-03-08 2022-06-13 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
AU2017240157B2 (en) 2016-04-01 2022-10-20 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
IL309259A (en) 2016-07-11 2024-02-01 Sage Therapeutics Inc C17, C20 and C21 converted neuroactive steroids and methods of using them
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス, インコーポレイテッド C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
CA3038900A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
NZ752732A (en) 2016-10-18 2024-08-30 Sage Therapeutics Inc Oxysterols and methods of use thereof
AU2017345399B2 (en) 2016-10-18 2022-02-24 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA56046A (fr) 2019-05-31 2022-04-06 Sage Therapeutics Inc Stéroïdes neuroactifs et compositions associées

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430942A (en) * 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
WO1994027608A1 (en) * 1993-05-24 1994-12-08 Cocensys, Inc. Methods and compositions for inducing sleep
WO1996040043A2 (en) * 1995-06-06 1996-12-19 Cocensys, Inc. Neuroactive steroids of the androstane and pregnane series

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ERCOLI ET AL: "Sugli Acidi Biliari e loro Derivati. Nota IV - Un Nouvo Metodo di Demolizione Graduale. Sua Applicazione alla Degradazione dell'Acido Litocolico", FARMACO., vol. 6, 1951, SOCIETA CHIMICA ITALIANA, PAVIA., IT, pages 547, XP001025589, ISSN: 0014-827X *
PETTIT G R ET AL: "BUFADIENOLIDES. 13. CONVERSION OF 3BETA-HYDROXY-17-OXOANDROST-5-ENE TO 3BETA-ACETOXY-5BETA,14ALPHA-BUFA-20,22-DIENOLIDE", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 36, no. 21, 22 October 1971 (1971-10-22), pages 3207 - 3211, XP002029626, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
US20050176976A1 (en) 2005-08-11
WO2002053577A2 (en) 2002-07-11
WO2002053577A3 (en) 2002-10-10
US7064116B2 (en) 2006-06-20
AU2002217353A1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
GR1003861B (el) Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
SG157231A1 (en) Substituted p-diaminobenzene derivatives
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
HUP0401108A2 (hu) Spirovegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
YU45403A (sh) Novi 1,2-difenil-azetidinoni, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena za lečenje poremećaja u metabolizmu lipida
TNSN07021A1 (fr) Derives de quinazoline -4-yl-piperidine et cinnoline -4-yl-piperidine servant d'inhibiteurs de pde10 pour le traitement de troubles du snc
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
NZ544591A (en) Pyrrolodihydroisoquinolines as PDE10 inhibitors
YU63202A (sh) Derivati 2-okso-1-pirolidina, postupci za njihovo dobijanje i njihove upotrebe
RS20050744A (en) Benzopyran compounds useful for treating inflammatory conditions
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
HK1129103A1 (en) Prodrugs of gaba analogs, compositions and uses thereof gaba
MX2007013263A (es) Novedosos derivados oxadiazol y su uso medico.
HK1068628A1 (en) Nicotinic acetyl-choline receptors inhibitor compounds, their preparation and use
ATE348831T1 (de) Diazabicyclische biarylderivate
DE60309740D1 (de) 1,4-dizabicyclo(3,2,2)nonane derivative, verfahren zur ihre herstellung und therapeutical verwendung
TW200504045A (en) Benzopyran compounds for use in the treatment and prevention of inflammation related conditions
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.
AU2002224847A1 (en) N-alkylated gaba compounds, processes for their preparation and their use as medicaments
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
BR0011039A (pt) Análogos de gaba substituìdos com 3-heteroarilalquila
WO2001080845A3 (en) (2-aminoethyl) oxime derivatives for the treatment of depression
ATE283838T1 (de) Wirksame derivate der valproinsäure zur behandlung von neurologischen und psychotischen störungen, und ein verfahren zu ihrer herstellung